Monthly information on share capital and company voting rights
- None.
- None.
Insights
The disclosure of the total number of shares and voting rights by Cellectis provides essential data for investors and market participants. This information is a key indicator of the company's current equity structure, which can influence shareholder value and corporate control dynamics. The total number of voting rights, in particular, is indicative of the potential for shifts in corporate governance and can affect the outcome of shareholder meetings, including the election of board members and approval of major corporate decisions.
Investors should note that the total number of voting rights exceeds the number of shares, which may suggest the existence of double voting rights for certain shareholders or the issuance of shares with differential voting rights. Such structures can impact minority shareholders and the market's perception of corporate democracy within the firm. Furthermore, these figures are crucial for the calculation of thresholds that may trigger mandatory takeover bids or disclosure requirements under French market regulations.
Understanding the equity structure of a company like Cellectis is vital for assessing market sentiment and forecasting potential stock performance. The data released indicates stability or changes in the equity structure, which can be a precursor to investor behavior. For instance, if the number of voting rights has significantly increased without a corresponding rise in share count, it may point towards strategic actions like stock option plans being exercised or convertible instruments being converted.
Market participants often track such changes to gauge the likelihood of increased volatility or shifts in stock ownership concentration, which can affect liquidity and marketability of the shares. Additionally, this information can be used to analyze the company's alignment with corporate governance best practices, which is increasingly becoming a factor in investment decisions.
The information provided is in compliance with Article 223-16 of the General Regulation of the French financial markets authority, which mandates transparency in the disclosure of voting rights and share counts. This legal requirement ensures that the market operates with a high degree of integrity and that all stakeholders, including potential and current investors, are well-informed.
The legal implications of these disclosures are significant as they may affect the regulatory obligations of the company and its shareholders. For example, crossing certain thresholds in voting rights can lead to mandatory reporting and can even trigger mandatory bid laws. It is crucial for shareholders to understand these nuances to navigate their rights and responsibilities effectively in the context of French corporate law.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, Jan. 08, 2024 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 12/31/2023 | 71,751,201 | 77,686,718 |
For further information on Cellectis, please contact:
Media contact:
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com
Investor Relations contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
Attachment
FAQ
What is the total number of shares in the capital for Cellectis?
How many voting rights does Cellectis have?
Who is the media contact for Cellectis?
Who are the investor relations contacts for Cellectis?
